DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
LIVE
USA The Motley Fool EN

Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

Mar 09, 2026 &03000909202631; 18:00 UTC www.fool.com Trending 4/5
Read original on www.fool.com ↗
Neutral impact
Sentiment score: -15/100
Moderate impact Short-term (days)
WHAT THIS MEANS
Eli Lilly stock remains relatively expensive despite a year-to-date decline, suggesting investors should carefully evaluate entry points. The analysis indicates potential value in waiting for a more significant pullback before accumulating positions.
AI CONFIDENCE
65% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
Eli Lilly
LLYStock
High volatility expected
Valuation concerns persist despite year-to-date decline; stock remains elevated relative to historical metrics
PRICE HISTORY
Loading chart...
SUGGESTED ACTION
Consider establishing positions on deeper pullbacks rather than current levels. Monitor for 10-15% additional decline or wait for earnings-driven volatility to create more attractive entry opportunities for long-term healthcare exposure.
KEY SIGNALS
Elevated valuation multiples despite recent weaknessRecommendation to await better entry pointYear-to-date decline insufficient to justify current pricingPotential pullback opportunity for value-conscious investors
SECTORS INVOLVED
HealthcarePharmaceuticals
Analysis generated on Mar 10, 2026 at 00:48 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by The Motley Fool. Always conduct your own research and consult a qualified financial advisor before making investment decisions.